Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Summit Therapeutics
Pharma
Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia
President Trump unveiled generic drug tariffs. Samsung Bio will buy PolyPepide for $1.8 billion. A U.S. biotech seeks an IPO first in Hong Kong.
Angus Liu
Jul 24, 2026 9:00am
Summit updates ivonescimab survival data ahead of PDUFA
Jul 22, 2026 10:58am
Akeso's 34% overall survival win comes with caveats
May 31, 2026 8:00am
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
May 27, 2026 11:25am
Summit, UCB-Candid, J&J—Fierce Pharma Asia
May 8, 2026 8:30am
Summit shares tumble on interim PD-1/VEGF trial miss
May 1, 2026 10:56am
